Clinical Trial: Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, O
Brief Summary: Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.
Detailed Summary:
Sponsor: Boehringer Ingelheim
Current Primary Outcome: Incidence for adverse event of gastrointestinal disorder [ Time Frame: up to 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Incidence for adverse drug reaction of gastrointestinal disorder [ Time Frame: up to 6 months ]
- Incidence of adverse events [ Time Frame: up to 6 months ]
- Incidence of adverse drug reactions [ Time Frame: up to 6 months ]
- Incidence of serious adverse events [ Time Frame: up to 6 months ]
- Incidence for adverse events Perforation, Ulcer and Bleeding (PUB) in the upper gastrointestinal tract [ Time Frame: up to 6 months ]
Original Secondary Outcome: Same as current
Information By: Boehringer Ingelheim
Dates:
Date Received: July 1, 2014
Date Started: October 2001
Date Completion:
Last Updated: July 4, 2014
Last Verified: July 2014
